1887

Access Microbiology open research platform logo

Volume 6, Issue 10

Inducible clindamycin resistance among clinical Gram-positive cocci in a tertiary hospital in Niger Republic Open Access

Graphical Abstract

Graphical abstract

Abstract

. Macrolide-induced resistance to clindamycin is a well-described mechanism leading to treatment failure. Herein, we determined the frequency and associated factors of inducible clindamycin resistance in Gram-positive cocci in a tertiary care hospital.

. A cross-sectional descriptive study was carried out between January and December 2022. -tests were performed as recommended by EUCAST 2021 guidelines on 100 non-duplicate clinical isolates of Gram-positive cocci to determine the prevalence of methicillin resistance and inducible clindamycin resistance among the collected isolates.

. Of the 100 Gram-positive cocci isolates, 56 (56.0%), 17 (17.0%) and 27 (27.0%) were respectively coagulase-negative staphylococci, and spp. Among spp., Group D Streptococci (15.0%) were the most isolated. Methicillin-resistant (MRSA) represented nine (53.0%) of the isolates. Constitutive (cMLSb) and inducible clindamycin resistance (iMLSb) phenotypes were detected in 36 (36.0%) and 14 (14.0 %) of the isolates, respectively. exhibited 38.4% of cMLSb and 13.7% of iMLSb. The result of multivariate analysis showed that age groups, gender, type of samples, provenance, and bacteria, were not significantly associated with Gram-positive cocci iMLSb phenotype.

. The study reported for the first time a high prevalence of inducible resistance of Gram-positive cocci strains to clindamycin in Niger Republic. This suggests the urgent need for the implementation of regular screening of these isolates and the wise use of clindamycin in clinical practice.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): clindamycin , erythromycin , inducible resistance , MRSA and Niger
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000708.v4
2024-10-01
2024-10-10
Loading full text...

Full text loading...

/deliver/fulltext/acmi/6/10/acmi000708.v4.html?itemId=/content/journal/acmi/10.1099/acmi.0.000708.v4&mimeType=html&fmt=ahah

References

  1. Yacouba A. Niger data Inducible clindamycin resistance. Figshare 2024 https://doi.org/10.6084/m9.figshare.25466677.v1
     [Google Scholar]
  2. Gajdács M, Ábrók M, Lázár A, Burián K. Increasing relevance of Gram-positive cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. Sci Rep 2020; 10:17658 [View Article] [PubMed]
     [Google Scholar]
  3. Rosi E, Pescitelli L, Ricceri F, Di Cesare A, Novelli A et al. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa. Dermatol Ther 2019; 32:e12792 [View Article] [PubMed]
     [Google Scholar]
  4. Vena A, Castaldo N, Magnasco L, Bavastro M, Limongelli A et al. Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) infection: what are the challenges?. Expert Opin Pharmacother 2023; 24:331–346 [View Article] [PubMed]
     [Google Scholar]
  5. Dhawan VK, Thadepalli H. Clindamycin: a review of fifteen years of experience. Rev Infect Dis 1982; 4:1133–1153 [View Article] [PubMed]
     [Google Scholar]
  6. Venditti M, Baiocchi P, Santini C, Galetta P, Tarasi A et al. Potential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant Staphylococcus aureus septicemia persisting under vancomycin therapy. Int J Antimicrob Agents 1995; 5:123–128 [View Article] [PubMed]
     [Google Scholar]
  7. Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21:544–550 [View Article] [PubMed]
     [Google Scholar]
  8. Andreoni F, Zürcher C, Tarnutzer A, Schilcher K, Neff A et al. Clindamycin affects group A streptococcus virulence factors and improves clinical outcome. J Infect Dis 2017; 215:269–277 [View Article] [PubMed]
     [Google Scholar]
  9. Armengol Álvarez L, Van de Sijpe G, Desmet S, Metsemakers W-J, Spriet I et al. Ways to improve insights into clindamycin pharmacology and pharmacokinetics tailored to practice. Antibiotics 2022; 11:701 [View Article] [PubMed]
     [Google Scholar]
  10. Ashwini M, Ray M, Sumana K, Halami PM. Prevalence of macrolide-lincosamide-streptogramin resistant lactic acid bacteria isolated from food samples. J Food Sci Technol 2023; 60:630–642 [View Article] [PubMed]
     [Google Scholar]
  11. Manandhar S, Shrestha R, Tuladhar RS, Lekhak S. Inducible clindamycin resistance and biofilm production among staphylococci isolated from tertiary care hospitals in Nepal. Infect Dis Rep 2021; 13:1043–1052 [View Article] [PubMed]
     [Google Scholar]
  12. Deotale V, Mendiratta DK, Raut U, Narang P. Inducible clindamycin resistance in Staphylococcus aureus isolated from clinical samples. Indian J Med Microbiol 2010; 28:124–126 [View Article] [PubMed]
     [Google Scholar]
  13. Assefa M. Inducible clindamycin-resistant Staphylococcus aureus strains in Africa: a systematic review. Int J Microbiol 2022; 2022:1835603 [View Article] [PubMed]
     [Google Scholar]
  14. Jarajreh D, Aqel A, Alzoubi H, Al-Zereini W. Prevalence of inducible clindamycin resistance in methicillin-resistant Staphylococcus aureus: the first study in Jordan. J Infect Dev Ctries 2017; 11:350–354 [View Article] [PubMed]
     [Google Scholar]
  15. Nahar L, Hagiya H, Nada T, Iio K, Gotoh K et al. Prevalence of inducible macrolide, lincosamide, and streptogramin B (inducible MLSB) resistance in clindamycin-susceptible Staphylococcus aureus at Okayama University Hospital. Acta Med Okayama 2023; 77:1–9 [View Article] [PubMed]
     [Google Scholar]
  16. Matuschek E, Brown DFJ, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect 2014; 20:255–266 [View Article] [PubMed]
     [Google Scholar]
  17. Vong O. CASFM / EUCAST AVRIL 2021 V1.0. Société Française de Microbiologie; 2021 https://www.sfm-microbiologie.org/2021/04/23/casfm-avril-2021-v1-0/
  18. Luchian I, Goriuc A, Martu MA, Covasa M. Clindamycin as an alternative option in optimizing periodontal therapy. Antibiotics 2021; 10:814 [View Article] [PubMed]
     [Google Scholar]
  19. Sunderkötter C, Becker K. Frequent bacterial skin and soft tissue infections: diagnostic signs and treatment. J Dtsch Dermatol Ges 2015; 13:501–524 [View Article] [PubMed]
     [Google Scholar]
  20. Hodille E, Badiou C, Bouveyron C, Bes M, Tristan A et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob 2018; 17:38 [View Article] [PubMed]
     [Google Scholar]
  21. Wilkins AL, Steer AC, Smeesters PR, Curtis N. Toxic shock syndrome - the seven Rs of management and treatment. J Infect 2017; 74:S147–S152 [View Article] [PubMed]
     [Google Scholar]
  22. Krutikov M, Rahman A, Tiberi S. Necrotizing pneumonia (aetiology, clinical features and management). Curr Opin Pulm Med 2019; 25:225–232 [View Article] [PubMed]
     [Google Scholar]
  23. Wang H, Zhuang H, Ji S, Sun L, Zhao F et al. Distribution of erm genes among MRSA isolates with resistance to clindamycin in a Chinese teaching hospital. Infect Genet Evol 2021; 96:105127 [View Article] [PubMed]
     [Google Scholar]
  24. Goudarzi M, Kobayashi N, Dadashi M, Pantůček R, Nasiri MJ et al. Prevalence, genetic diversity, and temporary shifts of inducible clindamycin resistance Staphylococcus aureus clones in Tehran, Iran: a molecular–epidemiological analysis from 2013 to 2018. Front Microbiol 2020; 11:
     [Google Scholar]
  25. Kishk RM, Anani MM, Nemr NA, Soliman NM, Fouad MM. Inducible clindamycin resistance in clinical isolates of staphylococcus aureus in Suez Canal University Hospital, Ismailia, Egypt. J Infect Dev Ctries 2020; 14:1281–1287 [View Article] [PubMed]
     [Google Scholar]
  26. Thapa D, Pyakurel S, Thapa S, Lamsal S, Chaudhari M et al. Staphylococcus aureus with inducible clindamycin resistance and methicillin resistance in a tertiary hospital in Nepal. Trop Med Health 2021; 49:99 [View Article] [PubMed]
     [Google Scholar]
  27. Abdollahi S, Ramazanzadeh R, Khiabani ZD, Kalantar E. Epidemiological and inducible resistance in coagulase negative staphylococci. Glob J Health Sci 2015; 8:109–119 [View Article] [PubMed]
     [Google Scholar]
  28. Raabe VN, Shane AL. Group B streptococcus (Streptococcus agalactiae). Microbiol Spectr 2019; 7: [View Article]
     [Google Scholar]
  29. Dilrukshi N, Kottahachchi J, Dissanayake T, Fernando N. Antibiotic sensitivity of group B Streptococcus from pregnant mothers and its association with resistance genes. Med Princ Pract 2023; 32:126–132 [View Article] [PubMed]
     [Google Scholar]
  30. Spížek J, Řezanka T. Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochem Pharmacol 2017; 133:20–28 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000708.v4
Loading
Inducible clindamycin resistance among clinical Gram-positive cocci in a tertiary hospital in Niger Republic
Access Microbiology 6, 000708.v4 (2024); https://doi.org/10.1099/acmi.0.000708.v4
/content/journal/acmi/10.1099/acmi.0.000708.v4
/content/journal/acmi/10.1099/acmi.0.000708.v4
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error